-transparent.png){kind=logo}
Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
May 1978,
The New England journal of medicine,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
January 1985,
Lijecnicki vjesnik,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
November 1973,
Harefuah,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
May 2012,
International journal of STD & AIDS,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
July 1978,
Lancet (London, England),
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
August 1984,
Onkologie,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
August 1988,
The American journal of medicine,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
October 1996,
International journal of dermatology,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
January 1983,
Clinical therapeutics,
T C Merigan, and
J G Gallagher, and
R B Pollard, and
A M Arvin
January 1988,
Pharmacotherapy,
